MediciNova, Inc.

NasdaqGM:MNOV Stock Report

Market Cap: US$97.6m

MediciNova Management

Management criteria checks 2/4

MediciNova's CEO is Yuichi Iwaki, appointed in Jan 2000, has a tenure of 24.33 years. total yearly compensation is $1.39M, comprised of 47.4% salary and 52.6% bonuses, including company stock and options. directly owns 2.23% of the company’s shares, worth $2.17M. The average tenure of the management team and the board of directors is 8.5 years and 5.5 years respectively.

Key information

Yuichi Iwaki

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage47.4%
CEO tenure25yrs
CEO ownership2.2%
Management average tenure8.5yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Apr 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Nov 27
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Jul 11
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Yuichi Iwaki's remuneration changed compared to MediciNova's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$657k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$620k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$3mUS$596k

-US$10m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$587k

-US$14m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$12m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$4mUS$572k

-US$13m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$3mUS$551k

-US$15m

Compensation vs Market: Yuichi's total compensation ($USD1.39M) is above average for companies of similar size in the US market ($USD645.01K).

Compensation vs Earnings: Yuichi's compensation has increased whilst the company is unprofitable.

CEO

Yuichi Iwaki (74 yo)

25yrs

Tenure

US$1,388,309

Compensation

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki served as Acting Principal Financial Officer at MediciNo...

Leadership Team

NamePositionTenureCompensationOwnership
Yuichi Iwaki
Co-Founder25yrsUS$1.39m2.23%
$ 2.2m
Kazuko Matsuda
Chief Medical Officer & Director13.3yrsUS$1.01m0.66%
$ 642.8k
Jason Kruger
CFO & Principal Financial Officer2.6yrsno datano data
David Crean
Chief Business Officer3.7yrsno datano data
John O'Neil
Controllerno datano datano data

8.5yrs

Average Tenure

58.5yo

Average Age

Experienced Management: MNOV's management team is seasoned and experienced (8.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yuichi Iwaki
Co-Founder24.3yrsUS$1.39m2.23%
$ 2.2m
Kazuko Matsuda
Chief Medical Officer & Director5.5yrsUS$1.01m0.66%
$ 642.8k
Hideki Nagao
Independent Director7.2yrsUS$69.23k0%
$ 0
Carolyn Beaver
Independent Director4.3yrsUS$69.23k0%
$ 0
Nicole Lemerond
Independent Director1.4yrsUS$46.16k0%
$ 0

5.5yrs

Average Tenure

66yo

Average Age

Experienced Board: MNOV's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:30
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MediciNova, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BuckB. Riley Securities, Inc.
Yen Ting ChenCredit Suisse
Jason KolbertD. Boral Capital LLC.